FOLD · As filed with the SEC
Amicus Therapeutics income statement, by quarter
The statement as Amicus Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | Q4 2025† 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 |
|---|---|---|---|---|
| Net product sales | 185,212† | 169,061 | 154,688 | 125,249 |
| Cost of goods sold | 26,547† | 19,467 | 15,217 | 11,698 |
| Gross profit | 158,665† | 149,594 | 139,471 | 113,551 |
| Operating expenses: | ||||
| Research and development | 23,741† | 23,415 | 60,848 | 27,839 |
| Selling, general, and administrative | 117,081† | 90,036 | 84,543 | 91,827 |
| Loss on impairment of assets | 0† | 0 | 1,702 | — |
| Restructuring charges | 0† | 0 | 0 | 0 |
| Depreciation and amortization | 1,897† | 1,874 | 1,852 | 1,837 |
| Total operating expenses | 142,719† | 115,325 | 148,945 | 121,503 |
| Income (loss) from operations | 15,946† | 34,269 | (9,474) | (7,952) |
| Other (expense) income: | ||||
| Interest income | 833† | 829 | 843 | 812 |
| Interest expense | (11,428)† | (11,711) | (11,565) | (11,455) |
| Other (expense) income | (2,208)† | 10,887 | 1,015 | 550 |
| Income (loss) before income tax | 3,143† | 34,274 | (19,181) | (18,045) |
| Income tax expense | (1,453)† | (16,968) | (5,239) | (3,641) |
| Net loss attributable to common stockholders | 1,690† | 17,306 | (24,420) | (21,686) |
| Net loss attributable to common stockholders per common share - basic (in dollars per share) | — | 0.06 | (0.08) | (0.07) |
| Net loss attributable to common stockholders per common share - diluted (in dollars per share) | — | 0.06 | (0.08) | (0.07) |
| Weighted-average common shares outstanding - basic (in shares) | — | 308,468,423 | 308,254,256 | 307,689,207 |
| Weighted-average common shares outstanding - diluted (in shares) | — | 310,433,494 | 308,254,256 | 307,689,207 |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.